Picture of Veracyte logo

VCYT Veracyte Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousMid CapHigh Flyer

Momentum

Relative Strength (%)
1m-1.86%
3m-17.36%
6m-34.7%
1yr+10.14%
Volume Change (%)
10d/3m+5.34%
Price vs... (%)
52w High-42.13%
50d MA-4.57%
200d MA-21.51%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)45.66
PEG Ratio (f)1.59
EPS Growth (f)40.42%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value1.79
Price to Tang. Book6.28
Price to Free Cashflow27.33
Price to Sales4.63
EV to EBITDA39.56

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital1.91%
Return on Equity2.86%
Operating Margin5.11%

Financial Summary

Year End 31st DecUnit202020212022202320242025E2026ECAGR / Avg
Total Revenue$m117.48219.51296.54361.05445.76491.86540.0329.93%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%n/an/an/an/an/a+45.47+36.81n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202531st Dec 2026
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2025 / 2026

Blurred out image of Veracyte EPS forecast chart

Profile Summary

Veracyte, Inc. is a global diagnostics company. The Company enables clinicians with insights they need to guide and help patients to diagnose and treat cancer. The Veracyte Diagnostics Platform delivers cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and an evidence-generation engine, which drives durable reimbursement and guideline inclusion for its tests, along with new insights to support continued innovation and pipeline development. The Company offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna) and bladder cancer (Decipher Bladder). It has developed the noninvasive Percepta Nasal Swab test to help physicians accurately and quickly determine lung cancer risk. All of its tests are serviced through its own Clinical Laboratory Improvement Amendments (CLIA) certified laboratories in South San Francisco, California, San Diego, California and Austin, Texas.

Directors

Last Annual
December 31st, 2024
Last Interim
March 31st, 2025
Incorporated
August 15th, 2006
Public Since
October 30th, 2013
No. of Shareholders
16
No. of Employees
824
Sector
Biotechnology & Medical Research
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Market
Shares in Issue
78,314,611

VCYT Share Price Performance

Upcoming Events for VCYT

Q2 2025 Veracyte Inc Earnings Release

Q3 2025 Veracyte Inc Earnings Release

Similar to VCYT

Picture of 89bio logo

89bio

us flag iconNASDAQ Global Market

Picture of Abivax SA logo

Abivax SA

us flag iconNASDAQ Global Market

Picture of ABPRO Holdings logo

ABPRO Holdings

us flag iconNASDAQ Global Market

Picture of AC Immune SA logo

AC Immune SA

us flag iconNASDAQ Global Market

Picture of Acrivon Therapeutics logo

Acrivon Therapeutics

us flag iconNASDAQ Global Market

FAQ